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Abstract: Acetylcholinesterase-inhibitory peptide has gained much importance since it can inhibit
acetylcholinesterase (AChE) and increase the availability of acetylcholine in cholinergic synapses,
enhancing cholinergic transmission in pharmacological treatment of Alzheimer’s disease (AD).
Natural peptides have received considerable attention as biologically important substances as a
source of AChE inhibitors. These natural peptides have high potential pharmaceutical and medicinal
values due to their bioactivities as neuroprotective and neurodegenerative treatment activities.
These peptides have attracted great interest in the pharmaceutical industries, in order to design
potential peptides for use in the prophylactic and therapy purposes. Some natural peptides and their
derivatives have high commercial values and have succeeded in reaching the pharmaceutical market.
A large number of peptides are already in preclinical and clinical pipelines for treatment of various
diseases. This review highlights the recent researches on the various natural peptides and future
prospects for AD management.
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1. Introduction
Acetylcholinesterase (AChE) (E.C.3.1.1.7) is a serine hydrolase which catalyzes the hydrolysis
of neurotransmitter acetylcholine into choline and acetic acid [1,2]. According to cholinergic
neurotransmission, acetylcholinesterase (AChE) inhibition would increase the levels of acetylcholine
in the brain, thus improving cholinergic synapses in Alzheimer’s disease (AD) patients [3–6].
The impairment of cognitive functions and the behavioral disruptions that affect patients with AD
are associated with deficiencies in cortical excitability, particularly cholinergic neurotransmission.
Disturbances of acetylcholine metabolism have been detected in the AD patient brains with higher
levels of AChE expression in decomposition of acetylcholine and deterioration in activity of choline
acetyltransferase (ChAT), an enzyme which is responsible for the synthesis of acetylcholine [7–9].
AD is a progressive neurodegenerative disorder with complex multifactorial pathogenesis,
memory impairment, and damaged cognitive skills, including attention, spatial orientation, judgment,
language disorder, motoric problem, and loss in healthy aging [10–12]. The main hallmark of
AD patient brain is characterized by extracellular senile plaques containing amyloid-β peptides
(Aβ) deposits, neurofibrillary tangles, progressive synapse loss, and severe oxidative stress [13,14].
Aβ-induced oxidative stress is triggered by protein oxidation, lipid peroxidation, free radical
formation, neuronal cell death via apoptotic pathway, DNA oxidation leading to DNA damage
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both in mitochondria and nucleus [15–18]. The most common form of AD syndrome is dementia.
Dementia is a clinical syndrome characterized by progressive decline in cognitive function as well as
behavioral disorders beyond the normal aging [19,20]. It is estimated that AD represents approximately
60–80% of all dementia cases [21,22]. Dementia mainly affects elderly and it is presumed that, by 2050,
more than 115 million people suffer dementia, which majority contributed by AD [23]. In fact, most of
the AD symptoms were related to loss of cholinergic function in the basal forebrain, the discovery of
AChE inhibition is important for the treatment of AD [24].
One of the best approach in devastating AD is based on accelerating decomposition of available
of acetylcholine which mainly improves the pathological symptom [25,26]. Inhibition of AChE is a
promising strategy to develop novel and causal therapeutics in AD treatment [27,28]. AChE inhibitors
are one of the most intensively probed categories of compounds in seeking an effective treatment of
AD [29,30]. Another member of the cholinesterase (ChE) family is butyrylcholinesterase (BChE), which
is also considered as promising target for AD drug discovery since the BChE activity increases in the
late stages of AD. A previous study reported that BChE inhibitors could act in a similar way as well as
AChE inhibitors, in particular to slow down cognitive decline [31]. AD drugs used recently as AChE
inhibitors include tacrine, rivastigmine, galantamine, metrifonate, and donepezil [32,33]. However,
these drugs may lead to injurious gastrointestinal side effects such as nausea, vomiting, diarrhea, and
anorexia [33–36]. Currently, there is no cure for AD and these drugs only can temporarily improve
symptoms or slow the progression of AD [37,38]. Thus, current approaches to the treatment of AD
targeting AChE need be developed.
The other safer sources that can be used as AChE inhibitors are obtained from natural peptides.
These peptides can be found in various sources, such as protein hydrolysates. Protein hydrolysate
is a good source of nutrients for health due to it contains a high natural peptide compounds.
Protein hydrolysates are well-known as mixtures of polypeptides, oligopeptides, and amino acids that
are manufactured from protein sources using partial hydrolysis [39–41]. The advantages of consuming
protein hydrolysate containing natural peptides due to its small molecular size thus easily absorbed in
the digestive tract and quickly delivered into the bloodstream reaching muscle tissue, immune cells,
internal organs, and brain cells. Protein hydrolysate is also known as food protein-derived peptides.
Animal experiments prove that protein-derived peptides in the form of bovine casein-derived peptide
(CH-3) are capable of preventing cognitive decline in Alzheimer’s disease of mice model with a
decreasing of inflammation and oxidative stress. The suppressive effect of CH-3 is mainly due to the
tripeptide: methionine-lysine-proline (MKP). Hence, this study suggests that CH-3 has therapeutic
potential for preventing cognitive impairment in AD [42]. Moreover, a previous study also reported
that 2,5-Diketopiperazine (DKP), also known as cyclic dipeptides which contain cyclo(-Phe-Phe), have
received considerable attention as biologically important molecules as a source of AChE inhibitory
peptide [43,44]. DKP can be synthesized from the N-terminus of amino acid residues of a natural linear
peptide and can be found in whey protein hydrolysates.
There is an abundance of natural peptides (NPs) which are known as specific protein fragments
and the majority have positive impacts on neurodegenerative preventives and treatments [45–49].
To date, more than 1500 different NPs have been studied as functional biomolecules including
neuropeptides in a database called ‘Biopep’ [50,51]. NPs display drug-like or neurodegenerative
treatment activities as neuropeptides have been reported in many previous studies [52–55].
Most natural neuropeptides were isolated using bioassays based on physiological impacts as well as
light responses, spontaneous potentials responsible for the rhythmic contraction of the gut, motor
patterns, or heartbeat frequency changes [56–58]. Neuropeptides noticed in a fraction form as
biologically functional molecules, have been identified and isolated from various natural sources,
and their activities were investigated in many medical and pharmaceutical purposes [59–62]. Here,
we present a review which is mainly concerned with NPs targeting AChE in the context of different
natural source matrices.
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2. Neuropeptides from Plant Sources
Plants are rich sources of pharmacologically bioactive agents and some studies of Portugal’s
medicinal plants showed great results for AChE inhibition with the species Melissa officinalis, Mentha
suaveolens, Laurus nobilis, Hypericum undulatum, and Sanguisorba minor [63,64]. These plants were used
in traditional medicines, in particular, for the treatment of nerve dysfunction or related problems over
three decades [64]. Recently, hemp seed peptides targeting AChE-inhibitory enzymatic hydrolysates
were obtained using six distinct proteases (pepsin, pepsin-pancreatin, alcalase, papain, flavourzyme,
and thermoase) at a range of concentrations (1–4%). The activity of hemp seed peptides showed
that about 1% pepsin hemp seed peptides had high activity of AChE inhibition with IC50 value was
~6 × 10−3 mg/mL compared to IC50 value was within 8–11.6 × 10−3 mg/mL from other enzymatic
hemp seed peptides. The analysis of mass spectrometry exhibited that most of the peptide sizes in
all the hydrolysate forms were less than 1000 Da: 244–1009 Da for the pepsin hemp seed peptides,
246–758 Da for the papain hemp seed peptides, and 246–607 Da for the alcalase hemp seed peptides.
The pepsin hemp seed peptides showed higher AChE-inhibitory effects which might be based on
the enhanced synergistic effects from a longer peptide size range when compared to the alcalase and
papain hemp seed peptides which had a smaller size range [53].
A more recent study following Tsai et al. [65] was the identification of the polysaccharide–peptide
complex in AChE inhibitory activities from the mushroom, Cordyceps militaris (CPSP) and
characterization of AChE inhibitory properties. The covalent bond of polysaccharide–peptide
complexes are attributed to O-glycosidic linkages in CPSP-F1 and N-glycosidic linkages in CPSP-F2
and CPSP-F3. The three polymers of CPSP-F1, CPSP-F2, and CPSP-F3 were extracted and separated
by ultrasound-assisted extraction and diethylaminoethanol (DEAE)–Sepharose CL-6B column
chromatography. Polysaccharide–peptide complexes were identified by DEAE-Sepharose CL-6B
column chromatography followed by high-performance gel-filtration chromatography. The results
showed that CPSP-F1 and CPSP-F2 had half maximal inhibitory concentrations of 32.2 ± 0.2 mg/mL
and 5.3 ± 0.0 mg/mL, respectively.
Meanwhile, the fruit peptides of Ziziphus jujuba, known as the jujube or Chinese date, a species of
Ziziphus in the buckthorn family Rhamnaceae, are being consumed worldwide due to their health
benefits, as both food and herbal medicine. As herbal medicine, one of the main functions of jujube
is to relax the brain by calming down the mind and improving sleep quality. Jujube is known
to possess neuroprotective activities, including protecting neuronal cells against neurotoxin stress,
stimulating neuronal differentiation, increasing expression of neurotrophic factors, and promoting
memory and learning [66]. A study showed that the Zizyphus jujube fruit exerts neurobiological
effects, especially antioxidant and anticholinesterase activities [67]. The fruit peptide of jujube was
introduced as a new peptide and named Snakin-Z, and consists of 31 amino acids with a sequence:
CARLNCVPKGTSGNTETCPCYASLHSCRKYG. The Snakin-Z activity showed considerable inhibition
against AChE. The half maximal inhibitory concentration (IC50) value of Snakin-Z against AChE
was 0.58 ± 0.08 mg/mL. This peptide has 80% enzyme inhibitory activity on AChE at 1.5 mg/mL.
The Snakin-Z also had high antioxidant activity (IC50 = 0.75 ± 0.09 mg/mL). Thus, it is suggested that
Snakin-Z might be beneficial for AD treatment [68]. Another beneficial part of the jujube is its seed.
Recent findings indicate that the seed of the jujube ameliorates an Aβ-induced synaptic long-term
potentiation (LTP) deficit in the hippocampal tissue through BDNF/TrkB signaling. This phenomenon
is induced by a regulatory effect of jujube seed on the post-translation modification of the brain-derived
neurotrophic factor (BDNF) [69].
The fermentation of some edible plants are also popular in the discovery of new AChE inhibitors.
A traditional Chinese salt-fermented soybean, known as commercial Douchi, has been determined to
have acetylcholinesterase (AChE) inhibitory activity. The results indicated that nineteen samples of
commercial Douchi showed various extents of AChE inhibitory activities. The IC50 value of AChE
inhibitory activities of Douchi extracts ranged from 0.040 to 2.319 mg/mL. Douchi extracts using
Aspergillus exhibited significantly higher AChE inhibitory activity than using Mucor and Bacillus [70].
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The other fermentation based product is sufu (fermented tofu), a traditional Chinese food, that has
been manufactured by fermenting soybean (yellow soybean & black soybean). Sufu was reported as
having AChE inhibitory activities. The bioactivities of anti-AChE from 15 brands of commercial sufu
samples were taken from various regions in China, and self-produced sufu produced by fermentation
with Actinomucor elegans 3.118, was successfully determined. The results indicated that sufu extract
performed significant inhibition activity toward AChE in vitro. It proved that sufu no. 5 had the
strongest inhibitory activity (IC50 = 0.191 mg/mL), while the prefermented sufu showed the highest
AChE inhibitory activity during sufu production. According to this result, it might be possible that
Chinese sufu could be considered in the treatment of Alzheimer’s disease patients [71]. The source
of fermented milks cultured with various probiotic strains could improve amyloid precursor protein
(APP) metabolism in Alzheimer’s disease. Fermented milk cultured with Lactobacillus helveticus
IDCC 3801 induced a strong decrease in the incidence of Alzheimer’s disease but also ameliorated
scopolamine-induced amnesia. This also suggests that the extract from fermented milk with L. helveticus
IDCC 3801 may improve APP metabolism and memory deficit [72].
Rice bran is one of bioactive food-derived peptides source and possesses the capability to enhance
positive health by decreasing chronic complication risks including obesity and aging diseases such
as AD. The high demand of rice bran in the global food market has supported extensive research on
natural peptides that are used both in prevention and treatment of AD. Fractions of peptides from rice
bran have been identified and characterized for potential inhibitory activities against AD. This peptide
showed nearly 45% reduction in cell cytotoxicity on amyloid-induced neuronal cells. Hence, rice
bran peptides could possibly to be used as natural nutraceuticals to help with the management of
AD [73,74].
3. Neuropeptides from Marine Sources
Approximately 70% of the Earth’s surface is covered by saltwater oceans which occupy more
than 90% of the biosphere [75,76]. Oceans are a rich source of bioactive compounds with diverse
structures and functions as well as potential therapeutic agents [75,76]. In recent years, many bioactive
compounds have been extracted from various marine animals like sea snails, sponges, soft corals,
marine fungus, marine algae, and marine microbes [77–81]. The exploration of new metabolites from
marine organisms has become popular, and approximately 10,000 bioactive compounds have been
successfully isolated including polysaccharides, enzymes/protein, minerals, vitamins, polyunsaturated
fatty acids (PUFA), alkaloids, phenols, terpenoids, and natural peptides [82–91]. Natural peptides
generally have 3 to 20 amino acid residues, with their functions dependent on the composition and
sequence length of amino acids. Natural peptides with a low molecular weight have an escalated
feasibility of permeability through the gut wall without any disruption, hence employing their
biological and functional activities [92,93].
Natural peptides were first discovered and isolated from marine organisms in the 1960s.
After the discovery of neurotoxins, studies on marine peptides were done, vastly in the 1980s [62].
Approximately more than 2000 natural peptides have been isolated, representing 1/10 of the total
bioactive compounds obtained from marine organisms [94]. Thus, there is abundant amount of
published articles relating to marine-derived peptide isolation. Since then, the explorations of marine
neuropeptides have continued with the purpose to assure their application in treatment or prevention
of neurodegenerative diseases.
3.1. Cone Snail Conotoxins
Conotoxins are neuropeptides isolated from venom of sea snail or cone snails (Conus sp.)
which normally consist of 10 to 30 amino acid (A.A.) residues with one or more disulfide bonds.
Conotoxins have a variety of AA compositions and reaction mechanisms, but most of them have not
been determined. The majority of conotoxins modulate the activity of ion channels. However, some
conotoxins are also capable of inhibiting cholinesterase. Over the last few decades, conotoxins have
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been the subject of pharmacological interest. The venom ofω-conotoxin from marine cone snails has
been proven to be a valuable device in neuroscience, employing a key role in the the identification and
characterization of Voltage-dependent calcium channel (VGCC) subtypes [95,96].
Other evidence of conotoxin mechanisms in the inhibition of cholinesterases can be found in insect
and mammalian nervous systems, in particular, presynaptic muscarinic receptors on the liberation of
acetylcholine from striatal cholinergic neurons were investigated. The electrically stimulated release of
[3H]-acetylcholine has been examined from rat striatal slices and its inhibition by carbachol are affected
by specific inhibitors of voltage-operated calcium channels of the N-type by ω-conotoxin GVIA.
The generated release of [3H]-acetylcholine was decreased byω-conotoxin GVIA, indicating that the
N-type channel was involved in the release of some neurotransmitters. The N-type channels were
responsible for approximately two thirds of neurotransmitters release. The release was >97% blocked
byω-toxins. In the imaging experiment on brain slices, where cholinesterases had been inhibited by
paraoxon, the inhibition of [3H]-acetylcholine release by endogenous acetylcholine accumulated in
the tissue could be exhibited by the escalation of the release after atropine addition. The inhibition
was high in slices with functional N-type channels. Thus, it was concluded that the N-type calcium
channel may contribute to the stimulation of acetylcholine release in rat striatum [97].
In a recent study, Minic et al. showed that the potential of venom toxins for the inhibition of
protein receptors in the human body was implicated in the pathophysiology of AD. AChE has been
identified as a promising target for treatment of cognitive impairments associated with Alzheimer’s
by applying its enzyme inhibitors. A conotoxin has been reported playing a role as an effective
inhibitor of acetylcholinesterase. The in silico study of a certain conotoxin has been designed
with acetylcholinesterase, and may open aspects in binding affinity and specificity improvement.
Docking studies were performed to structurally determine the binding interactions involved in the
binding pocket of venom toxins with acetylcholinesterase occupied by each toxin in complex with
acetylcholinesterase. The binding mode between each toxin and AChE was similar to conotoxin and
AChE. Hence, it is a great prospect to investigate conotoxins as potential reversible and irreversible
inhibitors of acetylcholinesterase for the treatment of the cognitive disorder of Alzheimer’s disease [98].
3.2. AChEIs from Sponges
Previous studies reported that aqueous and organic extracts of tropical marine sponges have
biological activities including sponge peptides towards AChE. Approximately 66 extracts were
obtained and screened from 35 marine sponge species from the Caribbean Sea (Curaçao) and from
8 marine sponge species from the Great Barrier Reef (Lizard Island). The extracts were dissolved
in aqueous and organic solvents then tested for anti-AChE activities. The most interesting findings
were acquired from extracts of Pandaros acanthifolium, Neofibularia nolitangere, Verongula rigida, Topsentia
ophiraphidites, and Ircinia felix. The inhibition activities against AChE from some sponges were generally
found to be weak. However, the methanolic extract of T. ophiraphidites showed stronger anti-AChE
activity compared to other sponge extracts [99].
Furthermore, the assessment activities of acetylcholinesterase inhibitors (AChEIs) of 134
extracts obtained from 45 species of marine sponges have been reported by Beedessee and
coworkers [100]. Microplate and Thin-layer chromatography (TLC) assays had revealed potent
activities of acetylcholinsterase inhibitors in two ethyl acetate sponge extracts: Pericharax heteroraphis
and Amphimedon navalis. Further investigated extracts were found to possess inhibitory kinetics by
exhibiting mixed competitive/noncompetitive inhibition. However, the pure peptides, such as AChEIs
from marine sponges, are still difficult to explore. Thus, the potential of marine sponges as a source of
AChEIs are essential in future, particularly the purification and characterization of solitary bioactive
compounds for their therapeutic applications in combating neurodegenerative diseases.
Turk et al. reported that approximately 33 deep-sea Antarctic marine sponges were successfully
screened in ethanolic extracts and they showed strong inhibition toward acetylcholinesterase.
The most eminent AChE activities were associated with the extracts from sponges belonging to
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the genus Latrunculia. While most of the AChE inhibition activities associate with known secondary
metabolites, some other immensely strong acetylcholinesterase inhibitors still associate to the unknown
compounds [101].
3.3. Marine Bacterial Peptides
A huge variety of bioactive compounds can be extracted from marine bacteria. This means that the
field of marine bioactive compounds, such as peptides, is continuously expanding. Recent advances in
biological techniques enable a high level interest in natural peptides being developed. An overview of
the discovery of new marine bacterial peptides with potential biological activities against AChE has
been widely explored.
Bacterial associates of marine soft corals and sponges with anticholinesterase activities were
extensively reported in the previous studies. Approximately 887 marine bacteria were screened in
a microplate-based assay for the potential inhibitions towards acetylcholinesterase, and around 140
marine bacteria (15.8%) were found to inhibit acetylcholinesterase found in the electric eel enzyme.
The majority of the active bacterial isolates were associated bacteria with soft corals and marine
sponges. The maximum inhibition was found about 54% by a bacterial strain M18SP4P, isolated
from the marine sponge Fasciospongia cavernosa. Based on its phenotypic properties and 16S rDNA
sequencing, the strain was identified as Bacillus subtilis. This result showed that acetylcholinesterase
inhibitors are quite common found in marine bacteria [102].
Fengwu et al. [103] reported that isolated endophytic bacteria which were screened from oysters
showed acetylcholinesterase inhibitory activity. Out of eight strains endophytic bacteria separated
from oyster, one of them had AChE inhibitory activity, which was identified as Bacillus subtilis, the
inhibition rate was 22.4%, and it increased 3.3-fold at 37 ◦C for 78 h incubation.
3.4. Marine Fungus Peptides
Marine fungi, particularly those associated with marine animals and plants, appear to be a
uniquely rich resource for secondary metabolites, such as antibiotic, antitumor, antiinflammatory,
antidiabetes, and anti-acetycholinesterase agents [104–107]. A study conducted by Wu et al. [107]
reported that Talaromycesone A, talaroxanthenone, and AS-186c were isolated from the culture broth
and mycelia of a marine fungus Talaromyces sp. strain LF458, displayed potent acetylcholinesterase
inhibitory activities with IC50 values were 0.00749, 0.00161, and 0.0026 M, respectively. All isolated
compounds were subjected to bioactivity assays.
4. Neuropeptides from Terrestrial Venomous Animal
Venomous animals are widely spread all over the globe. Several terrestrial vertebrates (reptiles,
birds, insects, and mammals) are also venomous [108,109]. Venomous animals permanently or
periodically exploit self-generated substances for self-defense or capture prey that are toxic to other
species and cause death, even in small doses [110,111]. Several venomous animals have special
venom glands to produce their venom, while others contain toxic substances in various body parts.
A number of animals have a specialized organ used for introducing their venom into prey’s body.
Major arthropods (scorpions, bees, and wasps) have multicellular glands attached to the stinging
apparatus. In most terrestrial venomous, animals such as spiders, snakes, and millipedes, their
venom glands are connected to their mouthparts and the venom is spurted into the body of prey
through prick or bite. The most studied of the venomous terrestrial animals are snakes, spiders,
and scorpions [112,113]. It is known that animal venoms are complex mixtures with compositions
depending on the species [114].
Bee venom obtained from stepwise fractionation with methanol, acetone, polyacrylamide,
Sephadex gels, and anion exchangers has been reported to contain the polypeptides minimine and
melittin. One of these polypeptides has a molecular weight of around 6000 Da. This polypeptide was
successfully inhibited growth of third-instar larvae with a LD50 dose value of approximately 0.005 µg.
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On the other hand, these polypeptides were also reported to have in vitro anti-acetylcholinesterase
activity [115].
The Taiwan snake (Bungarus multicinctus) possesses venom called α-bungarotoxin, a three-finger
α-neurotoxin that has action against the acetylcholine receptor (AChR). The remarkable three-finger
toxin fold has maximally thrived to use a distinct combination of functional groups to generate an armor
of certain targets of AChR subtypes [116]. Powerful inhibition of mammalian acetylcholinesterase was
detected in the venom of the green mamba snake, Dendroaspis anyusticeps. The compound responsible
for inhibiting AChE was isolated and purified by gel filtration on Sephadex G-50, followed by ion
exchange chromatography on Bio-Rex 70 and SP Sephadex C-25, respectively. These substances are
known as polypeptides, named fasciculins [117].
5. Neuropeptides from Venomous Amphibian
In general, amphibians have one or more efficacious neuropeptides in their dorsal skin secretions.
The most common neuropeptide belongs to amphibians of the frog genera, called caerulein, with
peptide sequence: [pEQDY(SO3)TGWMDF-NH2]. Caerulein has various biomedical activities at
nanomolar concentrations. The penetration of caerulein is known to be able to affect smooth
muscle contraction, reduce blood pressure, have gastrin-like activity, change satiety-related sedation,
and thermoregulation. The Australian frogs from genus Litoria have the capability to modify
caeruleins in different seasons. The Uperoleia genus of toadlets can produce a number of tachykinin-
and bombesin-type neuropeptides, including uperolein [pEPDPNAFYGLM-NH2], while froglets
of the genus Crinia can produce various disulfide-containing neuropeptides that cause smooth
muscle contraction at very small concentrations (nanomolar size), such as assigniferin 1 peptide,
RLCIPYIIPC-OH. These peptides can be used in the study of drug-induced pancreatitis as biomarkers
of autophagy and pancreatic cell apoptosis; autophagy malfunction is now considered a major
contributor to Alzheimer’s disease and other neurodegenerative disorders [118,119].
Amphibian defensive skin secretions are known to have a plethora of biologically-active peptides
that are structural and functional analogs of vertebrate neuropeptides. Wang et al. reported that the
amino acid sequences of two invertebrate neuropeptide analogs are IPPQFMRF amide (IF-8 amide) and
EGDEDEFLRF amide (EF-10 amide) isolated from the defensive skin secretions of two different species
of African hyperoliid frogs: Kassina maculata and Phylictimantis verrucosus [120]. These neuropeptides
represent the C-terminal tetrapeptide amides of both novel peptides: –FMRF amide and –FLRF amide,
reflecting the canonical structural motifs of the FMRF amide-related peptides (FaRPs) which are
recognized as the ubiquitous invertebrate neuropeptide family. FaRPs show the potential targets of the
defensive arsenal of amphibian tegumental secretions to invertebrate predators, and the possibility of
more novel peptides from amphibians may represent more potent vertebrate neuropeptides.
Siano et al. reported that the amphibian skin peptide found with sequence: TKPTLLGLPLGAG
PAAGPGKR-NH2 possessed a significant AChE. The present work demonstrates that subtraction of
the size of the peptide origin could potentially form new compounds with significant cholinesterase
inhibition activity [121].
6. Strategies for the Rational Design of Peptide as Therapeutic Leads
Peptide therapeutics are exclusively associated with lower production complexity compared
with protein-based biopharmaceuticals. This is of course beneficial, considering the low cost of drug
production, due to generally approaching those of small molecules. Therefore, peptides are in the sweet
spot between small molecules and biopharmaceuticals in many ways. Natural peptides are frequently
not immediately suitable for use as therapy because of intrinsic weaknesses, including poor chemical
and physical stabilities, and a short plasma half-life. Some of these weaknesses have been successfully
resolved through the conventional design of therapeutic peptides. Besides conventional natural
peptide design, the wide range of peptide technologies has been presenting new opportunities and
future directions within the peptide field. These include multifunctional peptides in cell penetration,
Molecules 2018, 23, 2344 8 of 21
as well as conjugation of peptide drugs and effective technologies focusing on selection routes of
administration [122,123]. Peptides have thrived as highly potent signal transduction molecules,
employing powerful physiological effects. Peptides are generally categorized by a relatively short
turning plasma half-life, as well as physicochemical properties for their use in biomedical and
pharmaceutical fields. Therefore, conventional rational design of peptide therapeutics has focused on
rectifying techniques to relieve susceptibilities [123]. Several modified natural peptides with activity
against acetylcholinesterase of Alzheimer’s disease are shown on Table 1.
Peptide toxicity has been evaluated mostly by investigating the hemolysis activity toward human
red blood cells [124]. The Melittin peptide is known to be high cytolytic in bioassays. Its action is
beneficial to block the electrostatic interactions that most peptides need to interact with microbes [125].
Toxicity assays should be conducted under conditions mimicking the environment that the peptides
will confront in the host cells [126]. In selected examples, the toxicity assays have been performed
in various in vitro mammalian cell cultures and in vivo animal model viabilities in the presence of
peptides [127,128]. Based on peptide stability, extracts obtained from different mammalian tissues or
commercially available proteases are well fit to determine peptide susceptibility to molecular target
degradation and may affect the peptide activities [129,130].
The decreasing number of approved drugs produced by the pharmaceutical industry, which is
accompanied by the increasing expense of R&D, is causing a high demand for alternative approaches
to increase pharmaceutical R&D productivity. This circumstance has supported a revival in peptide
research as potential drug candidates. New synthetic strategies for confining metabolism and
alternative routes of administration have appeared in recent years and produced a large number
of peptide-based drugs that are now being marketed. Peptide-based drug discovery will be important
for answering new therapeutic challenges [131].
6.1. Peptide Design by Chemical Synthesis
Since Bruce Merrifield invented the methods of solid-phase peptide synthesis (SPSS) in the early
1960s, an increasing number of research groups have focused on peptide synthesis. However, the
classical step-by-step procedures for peptide synthesis still has limitations, such as decreasing final
product purity after passing through several coupling steps. It is understandable that a challenging
method for the activation of a peptide terminal group needs protecting groups, both t-butoxycarbonyl
(Boc) and 9-fluorenylmethoxycarbonyl (Fmoc). Besides Boc and Fmoc, novel amino acid protecting
groups and new techniques have been largely introduced to improve the quality and quantity of
peptide products. The condensation of the peptide fragment method was a popular method for
peptide production in the 1980s. In contrast, the racemization rate and overall reaction still have
difficulties to be resolved. In overcoming these issues, Kent and coworkers introduced the peptide
coupling revolution by utilizing the chemoselective reaction of unprotected peptide segments, namely
native chemical ligation. Later on, a large number of studies have focused on the development of
propitious ligating techniques including the well-known click reactions, ligation of peptide hydrazides,
and ligation of 5-oxaproline with α-ketoacid-hydroxylamine [132–134].
Another promising strategy in rational peptide drug design is to improve the physicochemical
properties of natural peptides, which often have a tendency to aggregate and sometimes poorly
dissolve in water. As expected from chemical design strategies, the development of streamlined
techniques other than chemical conversion were highly needed for eco-friendly peptide synthesis to
avoid aggregation, such methods include the peculation of hydrophobic darns, which can be achieved
by substituting or catalyzing N-methylation of the incorporated amino acids. If solubility issues arise
in certain peptide drug candidates, the regular basis zone is on molecular charge allocation and the
isoelectric point (pI) of the peptides, which are related to favorable pH and purification to obtain the
desired final product [123].
The chemical optimization strategy of a therapeutic peptide is based on the structure–activity
relationship and/or quantitative structure–activity relationship studies of newly synthesized peptide
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derivatives, with the objective to improve bioavailability, limit biodegradation, reduce elimination, and
increase affinity or selectivity to its target or receptor. The main concern for the low oral bioavailability
of peptide drugs are presystemic enzymatic degradation and poor penetration of the intestinal mucosa.
According to Lipinski’s rule of five evaluations, some peptides may be poor candidates to shift
from the gastrointestinal tract to the circulatory system due to their unfavorable physicochemical
properties [135,136].
Many efforts have been done regarding enhancing drug delivery by designing drug substances
as prodrugs to improve drug penetration via transcellular pathways to treat patients. The other
alternative route goes through the paracellular pathway by modulating the intercellular junction
protein clusters. It is presumed that this approach has a remarkable future prospect in oral delivery
of large molecules such as peptides, proteins, and oligonucleotides. Moreover, this approach has the
potential to deliver large molecules to the brain as diagnostic and therapeutic agents for brain diseases
such as Alzheimer’s disease [137–139].
6.2. Peptide Design by Molecular Biological Approach
Bioactive peptides can be acquired immediately from living organisms by the hydrolysis of
proteins or by chemical synthesis and these approaches are not cost-effective. A biological expression
system using genetic techniques based on a fusion technology would be a more efficient method for the
production of bioactive peptides. However, the molecular biology research has led to the availability
of amino acid sequence data determined by the cloning and cDNA sequencing of genes [140].
The production of natural neuropeptides in competent host cells has been studied by Rosenfeld
and coworkers. They used alternative processing of the RNA transcribed from the appeared calcitonin
gene to obtain a messenger RNA production in neural tissue distinct from that in parafollicular cells
as called thyroid cells. The thyroid mRNA encodes a precursor to the hormone calcitonin whereas
that in neural tissues generates a designed neuropeptide, referred to as calcitonin gene-related peptide
(CGRP). This approach allows the application of recombinant DNA technology to analyze the complex
neurobiological systems in the absence of previous structural and functional information from living
organisms [141].
6.3. Peptide Product by Designed Enzymatic Degradation
Enzymatic hydrolysis of proteins is catalyzed by proteases, which cleave peptide bonds between
two amino acids consuming a molecule of water per bond cleaved. Hence, the continuous cleavage
of peptide bonds breaks down proteins into products of lower molecular weight such as peptones,
peptides, and amino acids. Independently of the type of food protein, the enzymatic hydrolysis process
commonly comprises the following stages. Grinding the raw material and homogenization in water (or
buffer), temperature equilibration, and pH adjustment to the optimum values of the enzyme employed,
followed by enzyme addition. Recently, ultrasonic assisted hydrolysis was evaluated with the purpose
of facilitating the production of low molecular weight peptides. Upon completion of the reaction, the
enzyme needs to be inactivated by heating or pH adjustment. Alternatively, continuous membrane
reactor, where the enzyme is continuously recycled to the reaction tank, might also be used in order to
stop the reaction and save enzyme costs.
Afterwards, the digested material, which contains the bioactive peptides, is separated from
the precipitate and lipids by several methods: centrifugation or decantation, fractionated, and
further stabilized by spray-drying. In utilizing an appropriate enzyme and having good control
over processing conditions including pH, temperature, enzyme/protein ratio, and time, are critical
points for the production of protein hydrolysates with good properties. Eventually, these process
variables determine the extent of the hydrolysis reaction for a protein–enzyme system. This is normally
indicated by the degree of hydrolysis (DH), which is defined as the percentage of peptide bonds
cleaved. There are several methods to determine the DH such as pH-stat, trinitrobenzenesulfonic
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acid (TNBS), O-phthaldialdehyde (OPA), trichloroacetic acid soluble nitrogen (SN-TCA), and formol
titration methods.
Several novel AChE-inhibitory peptides were discovered and their amino acid sequences were
elucidated. Hemp seed proteins (HSPs) were enzymatically hydrolyzed and the released peptides were
investigated as potential therapeutic agents. Membrane isolated HSPs (mHPI) were the most soluble
with >60% solubility at pH 3–9 when compared to 27% solubility of isoelectric pH precipitated proteins
(iHPI). However, iHPI formed emulsions with smaller oil droplet sizes (<1 µm) while mHPI formed
bigger oil droplets. The iHPI was subjected to enzymatic hydrolysis using different concentrations
(1–4%) of six proteases including pepsin, pancreatin, flavourzyme, thermoase, papain, and alcalase, to
produce various HSP hydrolysates (HPHs). Some of HPHs amino acid sequences were identified to
successfully produce and confirm the in vitro AChE-inhibitory activities. Subsequently, it could be
used as a prospective model for future design that may serve as potent AD therapeutic agents [142].
Table 1. Modified natural peptide analogs with activity against acetylcholinesterase of
Alzheimer’s disease.
Peptide ID Amino Acid Sequence IC50 (M) Source Parental Compound References
I5 Boc-VNLAG-OGal 34.46 × 10−6 Plant galanthamine [143,144]
KPF KLPGF 1.09 × 10−6 Animal Albumin [145]
ARP GMQGPAGSGWEEGSGSPPGVTPLFSP n.a. Animal AChE-R [146]
PF EQRPR n.a. Plant Protein hydrolysate [73]
Colivelin SALLRSIPAPAGASRLLLLTGEIDLP 10−13 Plant ADNF C-terminally fusedto AGA-(C8R)HNG17 [147]
AChE-peptide AEFHRWSSYMVHWK 0.33 Human AChE [148,149]
T14 KAEFHRWSSYMVHWK n.a. Human AChE [150–152]
T15 NQFDHYSKQDRCSDL n.a. Human AChE [150,151]
ARP: Acetylcholinesterase Readthrough Peptide; PF: peptide fraction; n.a.: not available.
7. Future Perspectives of Virtual Screening on Natural Peptides
In recent years, virtual screening has been used to assist the binding models suggestion between
bioactive natural products with their molecular targets systematically [153,154]. A combination of
pharmacophore modeling, virtual screening, and molecular docking studies provides information to
identify and design AChE inhibitors with higher selectivity [155]. In a previous study, a retrospectively
validated structure-based virtual screening (SBVS) protocol to identify potent AChE inhibitors has
been developed [156]. The construction and the retrospective validation of the SBVS protocol [156]
made use of the enhanced version of the database of useful decoys (DUD-E) [157]. The decoys in
DUD-E were selected from the ZINC database [158,159]. Therefore, we were tempted to apply the
validated SBVS protocol [156] to identify potent AChE inhibitors from natural products collected in
the newest version of the ZINC database, ZINC15 [159].
In total, 190,090 natural products from ZINC15 were subjected in the screening campaign.
Lipinski’s rule of five for drug likeness [160] was used as the first filter to discard nondruggable
compounds in this campaign [161,162]. The filter resulted in 79,711 compounds that remained to be
further screened virtually using the retrospectively validated SBVS protocol [156]. Only 23 compounds
were identified as potent AChE inhibitors. Thence, the overall hit rate was 0.01%, which was considered
as very low. Nevertheless, these identified potent compounds could serve as the pivotal compounds in
the development of drug for AD [163–165] since the database for the retrospective validation which was
compiled by Mysinger et al. [157] defined potent AChE inhibitors as inhibitors “with affinities (IC50,
EC50, Ki, Kd, and log variants thereof) of 1 µM or better”. The following are the ZINC code [159] of
the hit compounds: ZINC000253412911, ZINC000253411436, ZINC000095919360, ZINC000095486033,
ZINC000085549645, ZINC000085626729, ZINC000085629900, ZINC000085772672, ZINC000085772673,
ZINC000085641926, ZINC000085597045, ZINC000085595326, ZINC000014443683, ZINC000008791438,
ZINC000008765420, ZINC000002123767, ZINC000002104243, ZINC000002159521, ZINC000071318273,
ZINC000034074522, ZINC000049601562, ZINC000038993374 and ZINC000038661945. Notably, similar
to peptides, nine out of the 23 hits contained an amide bond (Table 2). On the other hand, the attempts
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to screen all virtual 400 dipeptides and 8000 tripeptides by employing the same SBVS protocol resulted
in zero hits. Therefore these nine compounds are of considerable and timely interest. Short molecular
dynamics (MD) simulations of enzyme-inhibitor using NAMD [166] by employing the SBVS results of
the compounds of interest as the starting points have been performed. These MD simulations were
performed to prioritize the compounds and to analyze the plausible AChE-ligand binding interactions.
The results indicate that compounds ZINC000002159521 and ZINC000038661945 are potential to be
further tested since their minimum total energy were lower than the minimum total energy of AChE
without ligand at MD simulations 0 to 200 ps (Table 2).
Table 2. Virtual screening hits containing amide bond and their minimum total energy values resulted
from short MD simulations as potential acetylcholinesterase inhibitors (AChEIs).
Compounds Total Energy Minimum * (kcal/mol)
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Figure 1 shows the interactions of compound ZINC000002159521 at its lowest total energy from
the MD simulations as a representative to examine the AChE-ligand binding interactions. The need
of an aromatic moiety in the ligand to bind to AChE binding pocket [156] is clearly seen in Figure 1.
The aromatic chromenone moiety from ZINC000002159521 is directly surrounded by aromatic residues
in the AChE binding pocket, i.e.: W84, Y130, F330, and Y442. On the other subpocket, the phenol
moiety from ZINC000002159521 is located adjacent to W279 and F290. Notably, the O carbonyl from
the amide bond in ZINC000002159521 serves as hydrogen bond acceptor for Y121. This indicates the
importance of amide bond for inhibitor to bind to AChE. Another identified hydrogen bond is the
bond between O hydroxyl from the phenol moiety in ZINC000002159521 as hydrogen bond acceptor
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to S286 by employing a water molecule for bridging the bond. These insights from molecular modeling
approaches could provide significant helps in the discovery and design novel AChE inhibitors.
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